6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

424B7 - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

424B7 - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

Craig Hallum initiated coverage of BioHarvest Sciences with a rating of Buy and set a new price target of $15.00

Maxim Group initiated coverage of BioHarvest Sciences with a rating of Buy and set a new price target of $12.00

First Hydration Formula Powered by VINIA's Blood Flow Technology Enters the $13 Billion U.S. Electrolyte MarketVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - December 3, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology platform, announces the U.S. launch of VINIA Blood Flow Hydration™, the first hydration solution powered by the blood flow benefits of VINIA's Piceid resveratrol to enter the $13 Billion US Electrolytes Drink Market*.Better Hydration Starts with Better Blood FlowFollowing overwhelmingly positive early-adopter interest, VINIA Blood Flow Hydration™ is n

Strong VINIA Momentum and New CDMO Win Delivers 39% Year-Over-Year GrowthCompany Fortifies Balance Sheet with Recent $19.9 Million Instiutional Equity Raise Following $14.7 Million Strengthening of Balance Sheet via Accelerated Warrant Exercises and Debt-to-Equity Conversions in SeptemberVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 13, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a biotechnology company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the third quarter ended September 30, 2025.Third Quarter 2025 Operational HighlightsAll figu

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 12, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that management has been invited to attend the Craig-Hallum 16th Annual Alpha Select Conference taking place on Tuesday, November 18th, 2025 in New York, NY. CEO Ilan Sobel is scheduled to host one-on-one meetings with institutional investors throughout the event as shown below. Craig-Hallum 16th Annual Alpha Select ConferenceDate: Tuesday, November 18, 2025Format: 1x1 Meetings OnlyLocation: Sheraton New York Times Square Hotel | New

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 10, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology platform, announces the closing of its previously announced underwritten public offering of 2,846,854 shares of common stock, no par value, and at a public offering price of $7.00 per share, which includes 361,854 shares issued upon the exercise by the underwriters of their option to purchase additional shares of common stock in the offering. The gross proceeds from this offering were $19.9 million, before deducting the underwriting discount and other offerin

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 7, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology platform, announces the pricing of an underwritten public offering of 2,485,000 shares of common stock, no par value, and at a public offering price of $7.00 per share. BioHarvest expects the gross proceeds from this offering to be approximately $17.4 million, before deducting the underwriting discount and other offering expenses. In connection with the offering, BioHarvest has granted the underwriters a 30-day option to purchase up to 372,750 additional share

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 6, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. In connection with the offering, BioHarvest also expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 4, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the third quarter ended September 30, 2025 after market close on Thursday, November 13, 2025.Management will host an investor conference call and webcast at 4:30 p.m. Eastern time on Thursday, November 13, 2025 to discuss the Company's third quarter 2025 financial results, provide a corporate update, and conclude with a question-and-answer session from telephone participants. To participate,

Partnership with "Saffron Tech" to Advance Production of One of the World's Most Valuable BotanicalsManagement Concurrently Shares Third Quarter 2025 Preliminary Results and Provides Guidance for the Fourth Quarter of 2025 Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - October 30, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) ("BioHarvest" or the "Company"), a biotechnology company pioneering its patented Botanical Synthesis technology platform, today announced it has entered into a strategic CDMO agreement with Saffron Tech, a company pioneering advanced cultivation methods for saffron — one of the world's most valuable and health-promoting botanicals — to develop and

Rehovot, Israel--(Newsfile Corp. - September 22, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) ("BioHarvest" or the "Company"), a biotechnology company pioneering its patented Botanical Synthesis technology platform, today announced the successful completion of a series of accelerated warrant exercises and conversions of debt to equity, which fortifies the Company's balance sheet with an additional $10.9 Million in gross proceeds and a concurrent $3.8 Million reduction in total debt.The following are the transactions which were executed subsequent to the Company's published Q2 2025 Financial Statements:Successfully raised $5.8 Million in incremental cash through the exercising of 898,277 w

Exosomes Produced in the Liquid Media of the BioHarvest Unique Large-Scale Bioreactors Add Potential New Revenue Stream from Products and CDMO OpportunitiesRehovot, Israel--(Newsfile Corp. - September 10, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it has successfully produced, at scale, plant-based exosomes in its bioreactor media, marking a significant advancement in the Company's proprietary Botanical Synthesis platform and in its ability to generate new revenue streams.Exosomes are nano-sized extracellular vesicles naturally secreted by plant cel

Veteran Technology Leader Brings 25+ Years of Financial and Capital Markets Experience to the BoardVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - January 22, 2025) - BioHarvest Sciences Inc., (NASDAQ:BHST) (CSE:BHSC) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology process, today announced that Mr. Sharon Malka has agreed to serve as an independent director of BioHarvest. The appointment is effective immediately."We are very pleased to announce the addition of Mr. Malka to the BioHarvest Board of Directors," said Dr. Zaki Rakib, Chairman of the Board and President of BioHarvest Sciences' CDMO Services Division

Strong VINIA Momentum and New CDMO Win Delivers 39% Year-Over-Year GrowthCompany Fortifies Balance Sheet with Recent $19.9 Million Instiutional Equity Raise Following $14.7 Million Strengthening of Balance Sheet via Accelerated Warrant Exercises and Debt-to-Equity Conversions in SeptemberVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 13, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a biotechnology company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the third quarter ended September 30, 2025.Third Quarter 2025 Operational HighlightsAll figu

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 4, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the third quarter ended September 30, 2025 after market close on Thursday, November 13, 2025.Management will host an investor conference call and webcast at 4:30 p.m. Eastern time on Thursday, November 13, 2025 to discuss the Company's third quarter 2025 financial results, provide a corporate update, and conclude with a question-and-answer session from telephone participants. To participate,

Robust 41% Year-Over-Year Revenue Growth, Driven by Strong Core Capsule and New Product SalesRehovot, Israel--(Newsfile Corp. - August 11, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the second quarter ended June 30, 2025.Second Quarter 2025 HighlightsAll figures stated in this news release are in U.S. dollars unless stated otherwise. Total revenues for the second quarter of 2025 increased 41% year-over-year to $8.5 million, in line with management guidance, with gross margins of 60% expanding by 800 basis points y

Rehovot, Israel--(Newsfile Corp. - August 4, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the second quarter ended June 30, 2025 before market open on Monday, August 11, 2025.Management will host an investor conference call and webcast at 8:00 a.m. Eastern time on Monday, August 11, 2025 to discuss the Company's second quarter 2025 financial results, provide a corporate update, and conclude with a question-and-answer session from telephone participants. To participate, please use the following information:Second Q

First Quarter Revenues Grew 47% to $7.9 Million, Exceeding Management GuidanceRehovot, Israel--(Newsfile Corp. - May 15, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the first quarter ended March 31, 2025.First Quarter & Subsequent 2025 Operational HighlightsAll figures stated in this news release are in U.S. dollars unless stated otherwise. Total revenues for the first quarter of 2025 increased 47% year-over-year to $7.9 million, exceeding management guidance, with gross margins expanding by 227 basis points to 58.

Rehovot, Israel--(Newsfile Corp. - May 1, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the first quarter ended March 31, 2025 after market close on Thursday, May 15, 2025.Management will host an investor conference call and webcast at 4:30 p.m. Eastern time on Thursday, May 15, 2025 to discuss the Company's first quarter 2025 financial results, provide a corporate update, and conclude with a question-and-answer session from telephone participants. To participate, please use the following information:First Quarter

Fourth Quarter Revenues Grew 62% to $7.3 Million, Exceeding Prior Management Guidance, with Full Year Revenues Increasing 99% Year-Over-Year to $25.2 MillionCDMO Division Secures Anchor Partnership with Tate & Lyle to Develop Next Generation of Plant-Based SweetenersRehovot, Israel--(Newsfile Corp. - March 31, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the fourth quarter and full year ended December 31, 2024.Fourth Quarter 2024 & Subsequent Operational HighlightsAll figures stated in this news release are in U.S.

Rehovot, Israel--(Newsfile Corp. - March 17, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2024 after market close on Monday, March 31, 2025.Management will host an investor conference call and webcast at 4:30 p.m. Eastern time on Monday, March 31, 2025, to discuss the Company's fourth quarter and full year 2024 financial results, provide a corporate update, and conclude with a question-and-answer session from telephone participants. To participate, please use the

Third Quarter 2024 Revenue Increased 101% Year-over-Year to Over $6.5 Million, Exceeding Management GuidanceVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 25, 2024) - BioHarvest Sciences Inc. (NASDAQ:BHST) (CSE:BHSC) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the third quarter ended September 30, 2024.Third Quarter & Subsequent 2024 Operational HighlightsAll figures stated in this news release are in U.S. dollars unless stated otherwise. Total revenues for the third quarter of 2024 increased 101% year-over-year to $6.5 million.Gros

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 18, 2024) - BioHarvest Sciences Inc. (NASDAQ:BHST) (CSE:BHSC) (FSE: 8MV) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the third quarter ended September 30, 2024 after market close on Monday, November 25, 2024.Management will host an investor conference call at 4:30 p.m. Eastern time on Monday, November 25, 2024, to discuss BioHarvest's third quarter 2024 financial results, provide a corporate update, and conclude with a question-and-answer session from telephone participants. To participate, pleas